KDI: Dialyzer, High Permeability With Or Without Sealed Dialysate System
What it covers
A high permeability hemodialysis system is a device intended for use as an artificial kidney system for the treatment of patients with renal failure, fluid overload, or toxemic conditions by performing such therapies as hemodialysis, hemofiltration, hemoconcentration, and hemodiafiltration. Using a hemodialyzer with a semipermeable membrane that is more permeable to water than the semipermeable membrane of the conventional hemodialysis system (§ 876.5820), the high permeability hemodialysis system removes toxins or excess fluid from the patient's blood using the principles of convection (via a high ultrafiltration rate) and/or diffusion (via a concentration gradient in dialysate). During treatment, blood is circulated from the patient through the hemodialyzer's blood compartment, while the dialysate solution flows countercurrent through the dialysate compartment. In this process, toxins and/or fluid are transferred across the membrane from the blood to the dialysate compartment. The hemodialysis delivery machine controls and monitors the parameters related to this processing, including the rate at which blood and dialysate are pumped through the system, and the rate at which fluid is removed from the patient. The high permeability hemodialysis system consists of the following devices:
(1) The hemodialyzer consists of a semipermeable membrane with an in vitro ultrafiltration coefficient (Kuf) greater than 8 milliliters per hour per conventional millimeter of mercury, as measured with bovine or expired human blood, and is used with either an automated ultrafiltration controller or anther method of ultrafiltration control to prevent fluid imbalance.
(2) The hemodialysis delivery machine is similar to the extracorporeal blood system and dialysate delivery system of the hemodialysis system and accessories (§ 876.5820), with the addition of an ultrafiltration controller and mechanisms that monitor and/or control such parameters as fluid balance, dialysate composition, and patient treatment parameters (e.g., blood pressure, hematocrit, urea, etc.).
(3) The high permeability hemodialysis system accessories include, but are not limited to, tubing lines and various treatment related monitors (e.g., dialysate pH, blood pressure, hematocrit, and blood recirculation monitors).
The identification in 21 CFR 876.5860, high permeability hemodialysis system. FDA gives KDI no definition of its own, so the regulation’s describes it.
FDA flags KDI devices as life-sustaining or life-supporting.
Recent clearances
| 510(k) | Device | Applicant | Decision | Type |
|---|---|---|---|---|
| K261267 | Careflux H60;Careflux H70;Careflux V500 | Fresenius Medical Care Renal Therapies Group, LLC | Jul 24, 2026 | Traditional |
| K252377 | NxStage System One with NxView | Fresenius Medical Care Renal Therapies Group, LLC | May 15, 2026 | Traditional |
| K260533 | ELISIO-H | Nipro Medical Corporation | Mar 19, 2026 | Special |
| K252459 | multiFlux 130 (F00013123); multiFlux 160 (F00013124) | Fresenius Medical Care Renal Therapies Group, LLC | Feb 10, 2026 | Traditional |
| K253412 | Tablo Hemodialysis System (PN-0008000, PN-0006000U) | Outset Medical, Inc. | Jan 26, 2026 | Traditional |
| K253518 | FX CorAL 40; FX CorAL 50 | Fresenius Medical Care Renal Therapies Group, LLC | Dec 18, 2025 | Special |
| K243920 | Purema H Hemoconcentrator - Pediatric | Medica USA, Inc. | Sep 19, 2025 | Traditional |
| K250508 | AK 98 Dialysis Machine (955607) | Vantive US Healthcare, LLC | Aug 1, 2025 | Traditional |
| K243237 | 2008T HD SYS. CDX BLUESTAR (191124); 2008T HD SYS. CDX W/bibag BLUESTAR (191126); 2008T HD SYS. W/O CDX BLUESTAR (191128); 2008T HD SYS. W/O CDX W/bibag BLUESTAR (191130) | Fresenius Medical Care Renal Therapies Group, LLC | Jun 13, 2025 | Traditional |
| K243505 | 5008X Hemodialysis System | Fresenius Medical Care Renal Therapies Group, LLC | May 30, 2025 | Traditional |
Clearances by year
100 KDI 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.
| Year | Clearances | Median days to decision |
|---|---|---|
| 2026 (so far) | 5 | 118 |
| 2025 | 9 | 199 |
| 2024 | 7 | 235 |
| 2023 | 7 | 157 |
| 2022 | 7 | 259 |
| 2021 | 2 | 207 |
| 2020 | 9 | 266 |
| 2019 | 4 | 263 |
| 2018 | 2 | 197 |
| 2017 | 8 | 188 |
| 2016 | 5 | 230 |
| 2015 | 5 | 69 |
| 2014 | 8 | 164 |
| 2013 | 11 | 247 |
| 2012 | 6 | 153 |
| 2011 | 5 | 85 |
Who submits
33 applicants cleared a KDI device since 2011. 84% of the clearances went to applicants in United States, then Italy (4%), Japan (4%) and Germany (3%). By type: Traditional 83%, Special 16% and Abbreviated 1%.
| Applicant | Clearances since 2011 |
|---|---|
| Fresenius Medical Care Renal Therapies Group, LLC | 19 |
| Nxstage Medical, Inc. | 13 |
| Nipro Medical Corporation | 8 |
| Outset Medical, Inc. | 8 |
| Fresenius Medical Care North America | 6 |
| Baxter Healthcare Corporation | 5 |
| Gambro Renal Products, Inc. | 4 |
| Asahi Kasei Medical Co., Ltd. | 3 |
How FDA classifies it
Class II. The special controls for this device are FDA's:
(1) “Use of International Standard ISO 10993 ‘Biological Evaluation of Medical Device—Part I: Evaluation and Testing,’ ”
(2) “Guidance for the Content of 510(k)s for Conventional and High Permeability Hemodialyzers,”
(3) “Guidance for Industry and CDRH Reviewers on the Content of Premarket Notifications for Hemodialysis Delivery Systems,”
(4) “Guidance for the Content of Premarket Notifications for Water Purification Components and Systems for Hemodialysis,” and
(5) “Guidance for Hemodialyzer Reuse Labeling.”
From 21 CFR 876.5860. Special controls are the requirements a 510(k) must show it meets.
Standards
21 CFR 876.5860 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent KDI clearances declared.
Ask about KDI
Questions about KDI
What is FDA product code KDI?
Product code KDI, “Dialyzer, High Permeability With Or Without Sealed Dialysate System” in FDA's classification database, is a Class II device type under 21 CFR 876.5860 (high permeability hemodialysis system), reviewed by FDA's Gastroenterology, Urology panel. FDA's 510(k) database lists 345 clearances under KDI, 100 of them since 2011.
How many 510(k) clearances are there under KDI?
FDA’s 510(k) database listed 345 clearances under KDI as of Oct 29, 2026, 100 of them decided since 2011; the most recent decision was Jul 24, 2026. The Predicate Finder searches the live database.
How long does FDA take to clear a KDI 510(k)?
For the 14 KDI clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 191 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.
Which companies have the most KDI clearances?
Since 2011: Fresenius Medical Care Renal Therapies Group, LLC (19), Nxstage Medical, Inc. (13), Nipro Medical Corporation (8), Outset Medical, Inc. (8) and Fresenius Medical Care North America (6). 33 applicants have cleared a KDI device in that time.